INTRODUCTION
The VEGF pathway is important in developmental and pathological angiogenesis. The role of VEGF-A in development is underscored by the embryonic lethality following inactivation of a single vegf-a allele in mice (Carmeliet et al., 1996; Ferrara et al., 1996) . VEGF-A also plays a key role in tumor angiogenesis (Ferrara et al., 2003; Kim et al., 1993) . Three VEGF pathway inhibitors (bevacizumab, sunitinib, and sorafenib) have been approved by the FDA as therapy for advanced cancer (Ellis and Hicklin, 2008; Ferrara et al., 2004; Kerbel, 2008) . At present, there is considerable interest in elucidating the mechanisms of refractoriness/resistance to anti-VEGF therapies (Ellis and Hicklin, 2008; Ferrara, 2010) .
VEGF-A binds two tyrosine kinase receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) (Ferrara et al., 2003) . Although both receptors are expressed in endothelial cells, VEGFR-1 is also expressed in other cell types including monocytes/macrophages and even some tumor cells (Fischer et al., 2008) . The VEGF-A effects are primarily mediated by VEGFR-2 (Ferrara et al., 2003) . In contrast, the role of VEGFR-1 is incompletely understood. Even though vegfr-1 null mice die in utero (Fong et al., 1995) , mice that express a VEGFR-1 lacking the tyrosine kinase domain (flt-1 tk À/À or vegfr-1 tk À/À mice) are viable and have no obvious vascular defects (Hiratsuka et al., 1998) . It has been postulated that, in this context, VEGFR-1 acts primarily as a nonsignaling ''decoy'' for VEGF-A and potentially other ligands (Hiratsuka et al., 1998; Park et al., 1994) . However, more recent studies indicate that, in a number of circumstances, VEGFR-1 signaling plays a role in tumor cell growth and metastasis or in pathological angiogenesis (Hiratsuka et al., 2001; Kerber et al., 2008; Luttun et al., 2002; Shibuya, 2001; Wu et al., 2006a; Wu et al., 2006b) . PlGF (Maglione et al., 1991 ) is a member of the VEGF family that binds to VEGFR-1 but not to VEGFR-2 (Park et al., 1994) . It has been suggested that PlGF plays a role in pathological angiogenesis (Autiero et al., 2003) , in wound healing (Carmeliet et al., 2001; , and in the recruitment of hematopoietic progenitors (Avecilla et al., 2004; Carmeliet et al., 2001; Hattori et al., 2002; Luttun et al., 2002; Lyden et al., 2001) . In particular, two findings suggested a role for PlGF in tumor angiogenesis. Although plgf À/À mice did not show any obvious vascular defects, plgf À/À embryonic stem cells developed small hypovascularized tumors when implanted in plgf À/À mice (Carmeliet et al., 2001 ). Also, treatment with an anti-PlGF monoclonal antibody (mAb) was reported to inhibit F4/80 + macrophage recruitment, angiogenesis, and tumor growth (Fischer et al., 2007) . In addition, anti-PlGF and anti-VEGFR2 mAb DC101 were reported to have additive effects in DC101-resistant tumors, suggesting that anti-PlGF may be useful as an adjunct to VEGF pathway inhibitors (Fischer et al., 2007) . The VEGF-Trap (Holash et al., 2002) , a chimeric soluble receptor that blocks VEGF-A, PlGF, and VEGF-B, is in late-stage clinical trials.
However, broad antitumor efficacy has not been typically observed in previous studies employing various PlGF/VEGFR-1 pathway inhibitors. Although genetic loss of VEGFR-1 signaling resulted in inhibition of PlGF-induced monocyte migration and metastasis as well as reduced primary growth of tumor cells overexpressing PlGF (Hiratsuka et al., 2001 (Hiratsuka et al., , 2002 , other studies reported that vegfr-1 tk À/À background (Dawson et al., 2009a; Hiratsuka et al., 2002) or administration of an anti-VEGFR-1 mAb (Dawson et al., 2009a; Lyden et al., 2001) does not markedly affect primary growth of several tumor transplants. Furthermore, whereas VEGFR2 blockade delayed angiogenesis and tumorigenesis in the Rip-TAG model of insulinoma, VEGFR-1 inhibition had no effect (Casanovas et al., 2005) . Finally, we have previously shown that mFlt(1-3)-IgG, a truncated soluble VEGFR-1 construct that potently blocks VEGF-A, VEGF-B, and PlGF (Davis-Smyth et al., 1996; Ferrara et al., 1998) , has similar antitumor efficacy to an anti-VEGF-A mAb (Shojaei et al., 2007) .
We sought to re-evaluate the role of PlGF in tumor angiogenesis by employing multiple approaches to inhibit PlGF function. The results presented here indicate that, independently of the status of the VEGF-A pathway, PlGF does not play a significant role in angiogenesis during primary tumor growth in mice.
RESULTS

Development and Characterization of Anti-PlGF mAbs C9.V2 and 7A10
We developed a panel of anti-PlGF mAbs from hybridoma and phage approaches and selected function-blocking candidates with different epitope specificities (Figure S1B available online, data not shown). These antibodies were selected for their ability to inhibit binding of mouse PlGF-2 to VEGFR-1 in plate assays (data not shown) and in cell-based assays ( Figures 1A, 1C, 1D , and 3C). Because there is a single PlGF isoform in mice, hereafter we will refer to mPlGF-2 as PlGF or mPlGF. 7A10 is a high-affinity, mouse-PlGF-specific rat mAb (dissociation constant [K D ] = 0.065 nM; Figure S1C , left panel) and, by cellbased assays, has an IC 50 (the concentration that results in half-maximal inhibition) of 0.4 nM ( Figure 1A) . The heavy and light chain variable regions of 7A10 were subcloned into mouse IgG2a and kappa constant domains, respectively. The resulting recombinant chimeric 7A10 mAb retained a nearly identical K D and IC 50 relative to the parental mAb (data not shown). 7A10 does not bind or block VEGF or hPlGF-2 ( Figure S1A and data not shown). C9.V2 is a mAb derived from a synthetic naive human antibody phage library and is able to block both mouse and human PlGF-2 without interfering with VEGF ( Figure S1A , right panel). The K D for this mAb is 0.9 nM ( Figure S1C , right panel), and the calculated IC 50 is 0.8 nM (Figure 1 A, left panel) . The neutralizing activity and potency of these two novel antiPlGF antibodies were further confirmed by their ability to inhibit PlGF-induced VEGFR-1 ( Figure 1C ) and MAPK phosphorylation ( Figure 1D ) in VEGFR-1-overexpressing 67NR (67NR-VEGFR-1) cells. In addition, we tested the ability of mAbs C9.V2 and 7A10 to block the interaction between PlGF and its coreceptors neuropilin (NRP)-1 and NRP-2 (Gluzman- Poltorak et al., 2000; Mamluk et al., 2002) . We found that 7A10 potently blocks the interaction between PlGF and NRP-1 ( Figure 1E ) and NRP-2 ( Figure S1D ). As expected, based on its mPlGF K D and IC 50 , C9.V2 appears to be a relatively less potent competitor of these interactions ( Figure 1E and Figure S1D ).
To compare the relative potencies of these new anti-PlGF antibodies with previously validated neutralizing mAbs, we took advantage of the ability of the 67NR-VEGFR-1 cells to migrate in response to VEGF-A or PlGF. Figures 1A and 1B show that the relative PlGF neutralizing potency of 7A10 and C9.V2 ( Figure 1A ) is even greater than the VEGF-A blocking activity of two anti-VEGF-A mAbs, G6-31 and B20-4.1 ( Figure 1B ). Pharmacokinetic studies in non-tumor-bearing C57BL/6 mice revealed that the half-lives (T 1/2 ) for the anti-PlGF antibodies 7A10 and C9.V2 are 8.8 and 3.1 days, respectively ( Figure S1F ). This is comparable to the T 1/2 of 7.8 days reported for the antiPlGF mAb described by Fischer et al. (2007) and is also similar to the half-lives of the two anti-VEGF-A antibodies used in this study (data not shown). Hence, even a single dose of 50 mg/kg of either anti-PlGF mAb is expected to cause a relatively lasting peak of approximately 500 mg/ml in circulation (See Figure S1F) . As PlGF plasma levels are about 100 pg/ml (Fischer et al., 2007) , the expected molar excess of anti-PlGF mAb to mPlGF in circulation is in the range of 1 3 10 6 to 1. Two additional hybridomaderived PlGF-blocking mAbs, 2D1 and 12D7, with K D , IC 50 , and T 1/2 values in between of those of 7A10 and C9.V2 were also tested (Figures S1E-S1G and data not shown).
Anti-PlGF Treatment Does Not Result in Inhibition of Angiogenesis or Primary Tumor Growth
We tested the ability of mAbs 7A10 and C9.V2 (30 mg/kg, three times per week) to affect the primary growth of the LLC, TIB48, B16F1, CT26, L1012, TIB6, and TIB42 tumor cell lines implanted subcutaneously in Balb/c nude mice. However, with the exception of LLC, we did not find any significant differences in tumor growth between the control mAb-treated group and the 7A10 or C9.V2 groups in any of the other tumor models tested. In contrast, anti-VEGF-A mAb (5 mg/kg twice weekly) showed efficacy in most models ( Figure 2A and Figures S2A-S2G ).
We assessed additional anti-PlGF antibodies in tumor models reported to be anti-PlGF sensitive (Fischer et al., 2007) . We tested the ability of anti-PlGF mAb 2D1 (50 mg/kg, three times per week) to inhibit the growth of CT26 tumors. However, 2D1 failed to inhibit CT26 tumor growth ( Figure 2B ). Also, we treated animals bearing EL4 tumors with the anti-PlGF antibodies 2D1, 12D7, or 7A10. Treatment with these mAbs (Figure 2B ), or with mAb C9.V2 ( Figures 2D, 2F , 5C, and 6C), had no effect on EL4 tumor growth.
We also probed the ability of the cross-reactive anti-PlGF mAb C9.V2 (50 mg/kg, three times per week) to affect growth of human tumor xenografts implanted in immunodeficient mice. Figure 2C shows that C9.V2 treatment did not inhibit growth of HM7, A673, or HT55 tumor xenografts. We also implanted HM7 and A673 tumor cells into vegfr-1 tk À/À , rag2
mice. However, we found no difference in tumor growth between the two genetic backgrounds (data not shown).
To further investigate the significance of PlGF in LLC tumor growth, we injected LLC cells in syngeneic, immunocompetent mice. As shown in Figure 2G , in this case anti-PlGF treatment with either C9.V2 or 7A10 mAb did not significantly inhibit tumor growth at any of the doses tested. Consistent with these data, LLC tumor growth was not inhibited when tumors were implanted in vegfr-1 tk À/À syngeneic immunodeficient background ( Figure 6A ). Next, we performed dose-responsive studies in immunocompetent tumor models previously reported to be sensitive to anti-PlGF treament (Fischer et al., 2007) . Figures  2D, 2E , and 2F show that, at all doses tested, neither 7A10 nor C9.V2 inhibited growth of B16F10, EL4, or CT26 tumors. In contrast, anti-VEGF-A mAb G6-31 (5 mg/kg twice weekly) resulted in significant tumor growth inhibition in all these three models. Finally, anti-PlGF treatment had no effect on primary tumor growth in the 66C14 and 4T1 orthotopic breast cancer models (Figures S2H and S2I) . A proposed mechanism for PlGF-induced angiogenesis is recruitment of VEGFR-1-positive macrophages (Fischer et al., 2007) . However, anti-PlGF did not decrease the number of CD11 + myeloid cells in circulation (data not shown), nor did it significantly decrease F4/80 + or CD11b + macrophage/myeloid cells in tumors at the end point of these studies (Figures S3A, S3C, and S3D). In agreement with the lack of antitumor efficacy, anti-PlGF treatment did not decrease microvascular density ( Figures S3A and S3B ).
Anti-PlGF Antibodies Inhibit Wound Healing and In Vivo
Growth of 67NR Cells Overexpressing VEGFR-1 Given the lack of antitumor efficacy of our anti-PlGF mAbs, we sough to thoroughly evaluate the ability of these reagents to neutralize PlGF in vivo.
Loss-and gain-of-function experiments have implicated PlGF in wound healing, especially in diabetic mice (Carmeliet et al., 2001; ). Thus, we tested the ability of 7A10 and C9.V2 to inhibit wound healing in a diabetic mouse model. Consistent with previous observations , Figure 3A (left panel) shows that rPlGF accelerates wound healing in Db/Db mice. In addition, systemic (IP) administration of either 7A10 or C9.2 mAb inhibited wound healing to levels comparable to the anti-VEGF treatment ( Figure 3A , right panel). Notably, the 5 mg/kg dose had a nearly identical efficacy as 50 mg/kg ( Figure S4B ), suggesting that even the lower dose of anti-PlGF is sufficient to systemically neutralize PlGF.
We considered the possibility that the lack of antitumoral efficacy of anti-PlGF mAb treatment might be due to suboptimal intratumoral delivery, degradation, and/or loss of PlGF-binding activity. However, as shown in Figure 3B (left panel), the serum concentrations of anti-PlGF mAb in tumor-bearing animals are similar if not greater than those previously reported by Fisher et al. Furthermore, at the end of these experiments, the PlGFblocking mAbs detected in tumor lysates were still fully functional ( Figure 3B , center panel) and at a vast molar excess with respect to the estimated levels of PlGF ( Figure 3B , right panel). Moreover, the concentrations of anti-PlGF mAbs in tumors and their molar excess with respect to PlGF were similar or higher than the concentrations and molar ratio of anti-VEGF mAbs in relation to VEGF-A at maximally efficacious doses ( Figure 3B , right panel).
We also tested mAbs C9.V2 and 7A10 for their ability to inhibit the in vivo growth of 67NR-VEGFR-1 cells. These cells proliferate in response to PlGF in vitro ( Figure 3C , left panel). As illustrated in Figure 3C (right panel), anti-PlGF treatment inhibited growth of 67NR-VEGFR-1 tumors but had no effect on growth of 67NR vector transduced cells. The 5 mg/kg dose had a nearly identical efficacy as 50 mg/kg.
Anti-VEGF-A Treatment Does not Increase Intratumoral Levels of PlGF
It has been reported that administration of the anti-VEGFR-2 mAb DC101 increases PlGF levels in circulation and PlGF LLC (C57BL/6 mice)
Time ( mRNA in tumors (Fischer et al., 2007) . However, we found that, in contrast to DC101, anti-VEGF treatment does not increase PlGF levels in circulation ( Figure 4A and data not shown). We also found that DC101 treatment increases plasma PlGF levels in non-tumor-bearing mice (data not shown), suggesting that this is a systemic response that occurs regardless of tumor implantation. We then measured the intratumoral PlGF concentrations during anti-VEGF-A or anti-ragweed treatment. Figure 4B shows that anti-VEGF-A treatment does not increase PlGF protein levels in any of the tumor models evaluated. Furthermore, as shown in Figure 4C , VEGF-A blockade with either G6-31, B20.4.1, and even DC101 mAb does not increase PlGF protein levels in CT26 tumor lysates.
Blocking VEGF-A and PlGF Does Not Result in Greater Efficacy than Anti-VEGF-A Monotherapy
We investigated whether PlGF blockade might enhance the response to VEGF-A inhibition in models previously described as resistant to VEGF pathway inhibitors, such as CT26, EL4, and LLC (Fischer et al., 2007; Shojaei et al., 2007) . We found that anti-VEGF-A treatment inhibits CT26 tumor growth more completely than DC101 ( Figure 5A ). Consequently, we tested the EL4 and LLC models, which show only a partial inhibition by anti-VEGF-A (Figures 2F and 2G ; Shojaei et al., 2007) . First we tested the efficacy of mFlt(1-3)-IgG, a soluble VEGFR-1 variant that inhibits PlGF, VEGF-A ( Figure S5 ), and VEGF-B and suppresses tumor growth in vivo (Gerber et al., 2000) . Consistent with previous studies (Shojaei et al., 2007) , the efficacy of mFlt1(1-3)-IgG was equivalent to that of anti-VEGF-A mAb ( Figures 5B and 5C ). To further corroborate these findings, we treated tumor-bearing mice with combinations of anti-PlGF mAbs 7A10 or C9.V2 and anti-VEGF mAb G6-31. As shown in Figures 5B and 5C , PlGF neutralization did not enhance the antitumor efficacy of anti-VEGF-A.
PlGF Blockade and/or Genetic Inhibition of Host VEGFR-1 Tyrosine Kinase Signaling Does Not Enhance the Antitumor Effects of Anti-VEGF We examined whether lack of host VEGFR-1 signaling might sensitize tumors to anti-VEGF-A treatment. We implanted the anti-VEGF-A refractory tumor cell lines LLC and EL4 in the vegfr-1 tk À/À and wild-type (WT) backgrounds. As shown in Figures 6A and 6B , lack of host VEGFR-1 TK signaling activity did not inhibit primary growth of LLC and EL4 tumors. Furthermore, the vegfr-1 tk À/À background also failed to inhibit primary tumor growth of HM7, A673, and B16F10 (data not shown and Figure 7A ). This lack of significant inhibition of primary tumor growth upon VEGFR-1 signaling blockade is consistent with previously published data (Dawson et al., 2009a (Dawson et al., , 2009b Hiratsuka et al., 2002; Kaplan et al., 2009; Lyden et al., 2001) . We then evaluated the effects of combining vegfr-1 tk À/À deficiency with VEGF-A blockade. As shown in Figures 6A and 6B , there were no significant differences in tumor growth between anti-VEGF mAb-treated WT and vegfr-1 tk À/À in LLC ( Figure 6A) and EL4 ( Figure 6B ) tumor-bearing mice. Although these findings do not rule out the possibility that VEGFR-1 signaling plays a role in tumor angiogenesis in other models (Hiratsuka et al., 2001; Kerber et al., 2008; Marcellini et al., 2006; Wu et al., 2006a) , they indicate that genetic ablation of this pathway in the stromal compartment does not generally sensitize anti-VEGF-A refractory tumors to respond to VEGF-A blockade.
We next tested whether combining PlGF blockade with loss of VEGFR-1 signaling might increase the antitumor efficacy of anti-VEGF treatment. As shown in Figure 6C , neither mFlt1(1-3)-IgG nor anti-PlGF 7A10 plus anti-VEGF G6-31 nor anti-PlGF C9.V2 plus anti-VEGF mAb G6-31 augmented the efficacy of anti-VEGF monotherapy in EL4 tumors implanted in vegfr-1 tk À/À mice. In addition, Figure 6D shows that tumor responses to the different treatments studied here are nearly identical in WT and vegfr-1 tk À/À backgrounds.
PlGF Blockade or Genetic Ablation of Host VEGFR-1 Signaling Reduces B16F10 Cell Extravasation to the Lungs but Does Not Inhibit Primary Tumor Growth
VEGFR-1 and PlGF have been previously implicated in the metastatic spread of B16 melanoma cells (Fischer et al., 2007; Hiratsuka et al., 2002; Kaplan et al., 2005 Kaplan et al., , 2009 Marcellini et al., 2006) . In addition, Fisher et al. reported that blockade of PlGF inhibits B16F10 primary tumor growth. However, genetic loss of host vegfr-1 tk (Dawson et al., 2009a; Hiratsuka et al., 2002) , administration of an anti-VEGFR-1 mAb (Dawson et al., 2009a; Lyden et al., 2001 ), or VEGFR-1 knockdown in bone marrowderived cells (Kaplan et al., 2009 ) did not markedly affect primary growth of B16 tumors. In agreement with these data, we found that inhibition of PlGF with two different mAbs ( Figure 2E ) or genetic loss of host VEGFR-1 TK signaling ( Figure 7A ) does not result in significant inhibition of B16F10 primary tumor growth. However, loss of VEGFR-1 TK signaling significantly decreased the number of intravenously injected B16F10 cells that establish metastatic nodules in the lungs ( Figure 7B ). These data suggest that VEGFR-1 signaling plays a role in B16F10 cell extravasation, and that blockade of PlGF or VEGF-A might have antimetastatic effects in this model. and 7D). Importantly, the 5 mg/kg dose of anti-PlGF 7A10 was sufficient to achieve maximal inhibition ( Figure 7D ). However, the volume of individual metastases was not significantly affected by anti-PlGF treatment (data not shown). These data are consistent with the hypothesis first proposed by Hiratsuka et al. that PlGF/VEGFR-1 signaling is primarily involved in facilitation of tumor migration or invasion rather than in tumor angiogenesis (Hiratsuka et al., 2002; Kaplan et al., 2005) .
DISCUSSION
PlGF was identified 19 years ago (Maglione et al., 1991) , but the significance of this molecule is still a matter of debate. Notably, studies addressing the role of PlGF in various models yielded conflicting results. Some investigators reported that PlGF has potent mitogenic and angiogenic effects (Odorisio et al., 2002; Ziche et al., 1997) , while others were unable to document such effects (Cao et al., 1996; Park et al., 1994) . PlGF overexpression enhanced tumor growth in some models (Hiratsuka et al., 2001; Marcellini et al., 2006) , but in others PlGF paradoxically had an inhibitory effect, presumably through formation of VEGF/PlGF heterodimers, which can downregulate VEGFR2 signaling (Eriksson et al., 2002; Schomber et al., 2007) . Recently, Fisher et al. reported that treatment with an antiPlGF mAb has antiangiogenic effects during primary tumor growth in all tumor models tested. However, the same group subsequently reported that genetic ablation of PlGF has no effect on the growth of pancreatic islet tumors in the RIP-Tag model (Fischer et al., 2008) . Here we show that neutralization of PlGF, genetic ablation of host PlGF receptor signaling, or combined anti-PlGF treatment and loss of host VEGFR-1 TK signaling do not inhibit angiogenesis during primary tumor growth. This lack of efficacy was observed with various reagents and most tumor models tested in immunodeficient and immuno- competent animals. Importantly, despite the lack of antitumor efficacy, the novel anti-PlGF antibodies used in the present study blocked endogenous PlGF signaling, as demonstrated by their ability to inhibit (1) wound healing in Db/Db mice, (2) growth of VEGFR-1-overexpressing tumors, and (3) B16F10 cell extravasation to the lungs.
Although in three independent experiments we observed an $30% inhibition of LLC tumor growth by anti-PlGF treatment in the balb/c nude background ( Figure 1A) , the same treatment failed to inhibit LLC growth when tumor cells were implanted in a syngeneic C57 black 6 background ( Figure 2G ). Although the reasons for such discrepancy remain unclear, it is possible that the efficacy of anti-PlGF in the context of allogenic LLC tumors reflects modulation of innate immune responses (Hattori et al., 2002; Murakami et al., 2006) , rather than inhibition of angiogenesis. In this context, it is noteworthy that genetic inhibition of host VEGFR-1 TK signaling (Dawson et al., 2009a; Hiratsuka et al., 2002) or anti-VEGFR-1 treatment (Dawson et al., 2009a; Lyden et al., 2001) did not inhibit LLC primary growth in syngeneic mice.
Interestingly, 67NR-VEGFR-1 but not the control 67NR-vector tumors were growth-inhibited by anti-PlGF treatment. However, the 67NR-VEGFR-1 cells overexpress VEGFR-1 and do proliferate in response to PlGF stimulation ( Figure 3C, left panel) . Therefore, the responsiveness of 67NR-VEGFR-1 tumors to anti-PlGF is likely due to direct inhibition of VEGFR-1 signaling in tumor cells rather than inhibition of angiogenesis. Nevertheless, these findings raise the possibility that anti-PlGF, similar to anti-VEGFR-1 mAb (Wu et al., 2006a (Wu et al., , 2006b , may be useful for inhibiting growth of VEGFR-1 signaling-dependent tumors.
PlGF and VEGFR-1 have been previously implicated in B16 metastasis (Fischer et al., 2007; Hiratsuka et al., 2002; Kaplan et al., 2009; Marcellini et al., 2006 ). Therefore, we tested the ability of our anti-PlGF antibodies to inhibit B16F10 cell extravasation into the lungs. Our results confirm the involvement of PlGF and VEGFR-1 signaling in regulating B16F10 metastasis under the experimental conditions tested. We believe that these are true ''on-target'' effects, based on the following observations: (1) similar anti-metastatic effects were obtained with two independent antibodies; (2) maximal inhibition was achieved at a low dose of antibodies, consistent with the high binding affinity of these reagents; (3) genetic inhibition of host VEGFR-1 TK signaling also inhibited B16F10 lodging. These findings raise the possibility that anti-PlGF may have a role as an antimetastatic treatment. However, very recent studies suggest that the role of VEGFR-1 signaling in metastasis is, at least in part, model or context dependent (Dawson et al., 2009a (Dawson et al., , 2009b Kaplan et al., 2009 ). Indeed, we found that antiPlGF mAb treatment does not inhibit metastasis in an orthotopic model (data not shown). Further studies are needed to address these issues.
The reasons for the discrepancies between our data and the results published by Fisher et al. are currently unknown. However, it is important to note that the conclusions of these authors were based on testing a single PlGF-blocking reagent. In contrast, the conclusions of this manuscript rely on the effects of four different anti-PlGF mAbs, genetic disruption of host PlGF receptor signaling, combination of both, or blockade of all VEGFR-1 ligands with mFlt(1-3)-IgG. Thus, the cumulative data presented here indicate that the efficacy of Fisher's anti-PlGF mAb is possibly due to off-target effects. Indeed, off-target effects are not uncommonly observed in the presence of high doses of certain monoclonal antibodies. Furthermore, not only have the Fc domains of some IgGs been previously shown to trigger anti-inflammatory reactions, but Fc-induced citotoxicity has also been previously implicated in the antitumor efficacy of known therapeutic antibodies (Clynes et al., 2000; Oflazoglu et al., 2007; Samuelsson et al., 2001) . In this context, the doseresponse curve for the effects of anti-PlGF mAb, showing that a maximal effect requires the dose of 50 mg/kg, is surprising. At this dose, Fisher et al. reported a very large excess of antibody with respect to PlGF, at least in the plasma (approx. 1.8 3 10 6 to 1) (Fischer et al., 2007) . Taking also into account the reported high binding affinity of this mAb for PlGF, the finding that only a 2-fold lower dose was not maximally efficacious is unexpected (Fischer et al., 2007) . In contrast, anti-PlGF mAbs with comparable affinity and pharmacokinetic characteristics had no significant effect on primary tumor growth even at the highest dose tested, even though they inhibited metastasis, wound healing, and growth of VEGFR-1-expressing tumors with a maximal effect at doses as low as 5 mg/kg.
In conclusion, we have provided multiple lines of evidence indicating that PlGF blockade does not result in inhibition of primary tumor growth in most models. While we cannot rule out the possibility that PlGF inhibition may have different effects in tumor models that we did not test, our findings argue against broad antiangiogenic or antitumor efficacy in anti-VEGF-resistant tumors. In this context, it is intriguing that a phase III study in pancreatic cancer patients, testing the VEGF-Trap in combination with gemcitabine, was recently stopped following the determination that, similar to bevacizumab, such treatment would not increase survival relative to gemcitabine alone (reviewed in Ferrara, 2010) . These findings indicate that, at least in this circumstance, the simultaneous inhibition of VEGF-A and PlGF (and VEGF-B) does not confer enhanced tumor suppression relative to specific VEGF-A blockade.
EXPERIMENTAL PROCEDURES Cell Migration Assay
Migration assays were performed in transwell membranes (8 mm pore size) inserted in 24-well plates (Corning Costar). Membranes were coated with a solution of 10 mg/ml collagen type I (BD) in PBS for 1 hr at 37 C, then washed and air-dried before use. 67NR-VEGFR-1 cells were grown in IMDM containing 10% fetal bovine serum (FBS) until they were 80% confluent and then starved in serum-free IMDM for 5 hr. Cells where then trypsinized and plated into migration inserts (20000 cells/insert in IMDM). PlGF or VEGF (R&D, Minneapolis, MN, USA) was added to the lower wells filled with IMDM containing different concentration of the corresponding mFlt-1(1-3)-IgG, anti-VEGF-A, or anti-PLGF mAb. The plates were incubated for 18 hr at 37 C. Cells on the top of the membrane were carefully wiped off. Cells on the bottom of the membrane were fixed with 100% ethanol for 5 min and stained with hematoxylin for 10 min and then rinsed off gently with running water. The number of migrated cells in each well was then quantified by counting 5 randomly chosen fields at 1003 magnification. Each determination represents the mean of 3 individual wells ± standard deviation (SD). Experiments were repeated at least three times. culture plates at a density of 2 3 10 3 cells/well. Twenty-four hours after seeding, cells were starved for 3 hr, then stimulated with rmPLGF (from R&D) 10 ng/ml, mPLGF 50 ng/ml plus aPLGF C9.V2 and 7A10 (10 mg/ml), rmVEGF (From R&D) 50 ng/ml, and rmVEGF 50 ng/ml plus mAb G6-31 10 mg/ml for 60 hr. After 60 hr, medium was removed and the cells were incubated for 2 hr with a BrdU labeling solution containing 10 mM BrdU. The assay was performed according to the manufacturer's instructions. Culture medium alone was used as a control for nonspecific binding.
Cell Proliferation Assay
VEGFR-1 Phosphorylation Assay 67NR cells (6 3 10 6 per 10 cm dish) were grown in Iscove's Modified Dulbecco's Medium (IMDM, GIBCO) with 10% FBS until 80% to 90% confluent. After 5 hr serum starvation, cells were stimulated with PlGF 50 ng/ml, PLGF 50 ng/ml plus aPLGF C9, or 7A10 (10 mg/ml), VEGF 50 ng/ml, VEGF 50 ng/ml plus aVEGF G6 10 mg/ml, control IgG aRagweed 10 mg/ml. After 10 min, the cells were lysed in cell lysis buffer (Cell Signaling Technology, Beverly, MA, USA) containing Phosphatase Inhibitor Cocktail 1 1:100 dilution and PMSF 1 mM (Sigma, St. Louis, MO, USA). The cell lysates were centrifuged at 13,000g for 10 min at 4 C, and the resulting supernatant was incubated with FLT-1 antibody (2 mg/ml) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) overnight at 4 C. Immunocomplexes were captured by incubating with EZview
Red Protein A Affinity Gel (Sigma) and immunoprecipitated proteins were subjected to immunoblotting analysis using a p-Tyr(PY99) mAb (1:2000 dilution) (Santa Cruz Biotechnology, Inc.). Proteins were visualized by using an ECL kit. For total VEGFR-1, blots were reprobed with an anti-FLT-1 antibody (1:500 dilution) (R&D).
PlGF/NRP1 and PlGF/NRP2 Competition Binding Assay Microtiter plates (Nunc, Rochester, NY, USA) were coated with recombinant mouse PlGF (BioVision, Mountain View, CA, USA) either at 2 mg/ml (for PlGF/ NRP1 binding) or at 4 ug/ml (for PlGF/NRP2 binding) in PBS. After an overnight incubation at 4 C, assay plates were washed with wash buffer (PBS/0.05%
Tween 20) and treated with block buffer (PBS/0.5% BSA) for 1 to 2 hr. Samples were serially diluted in sample diluent (PBS/0.5% BSA/15ppm Proclin/0.05% Tween 20/0.2%BGG/0.25% CHAPS/5 mM EDTA/0.3 M NaCl, pH 7.4) containing 0.25 mg/ml of heparin (Sigma) and incubated in the presence of either 100 ng/ml of biotin-mouse NRP1-Fc (0.66 nM for PlGF/NRP1 binding) or 425 ng/ml of biotin-NRP2-Fc (6 nM for PlGF/NRP2 binding). After incubation for 2 hr, assay plates were washed six times with wash buffer and then incubated for 45 to 60 min with AMDEX streptavidin-HRP (GE Healthcare, Pittsburgh, PA, USA) diluted 10,000-fold in assay buffer (PBS/0.5% BSA/0.05% Tween 20, pH 7.4). After washing (six times), detection step was carried on using tetramethylbenzidine (TMB) substrate (Moss Inc., Passadena, MD, USA). Absorbance was measured at 450 nm against a reference wavelength of 620 nm.
Subcutaneous Tumor Models
Tumor cells (1 3 10 6 ) were subcutaneously inoculated in the dorsal flank of mice of different genotypes, as indicated in the figures. Antibodies were IP injected at the doses indicated in the corresponding figure legends. Treatments with the anti-PlGF mAbs described in this manuscript or with anti-VEGF mAb G6-31 or B-20.4.1 (Liang et al., 2006) were initiated 24 hr after tumor cell inoculation. For syngeneic tumor models, EL4, LLC, and B16F10 cells were implanted in C57BL/6 mice, while CT26 cells were implanted in balb/c mice. All tumor growth experiments were performed at least three times and conducted in accordance with the Guide for the Care and Use of Laboratory Animals. An Institutional Animal Care and Use Committee (IACUC) approved all animal protocols.
Wound Healing Assay
Eight-week-old female C57BL/6 or Db/Db mice were used in this study. The indicated doses of antibodies were administered at day À4 and day À2 and then every other day from day 0 until day 10. Circular wounds of 6 mm diameter were generated at the scapular region of anesthetized females by excising skin and the subcutaneous fat and muscle panniculus carnosus using a punch (Stiefel, Olfenbach, Germany mice. Shortly after tumor cell inoculation, animals were treated with antiPlGF mAb 7A10 (5, 20, 50 mg/kg) or C9.V2 (50 mg/kg). Antibodies were administered thereafter three times per week. Anti-VEGF mAb B20.4.1 was administered twice weekly at the dose of 5 mg/kg. two to three weeks after tumor cell injection, lungs were washed, inflated, and subsequently collected. Lung preparations, imaging, and analysis were conducted as described in the Extended Experimental Procedures. Metastatic nodules were counted in a blinded fashion by superficial counting under the microscopy and/or by quantification of Micro-CT acquired images. Both methods gave similar results. All the metastasis experiments were repeated three times and conducted in accordance with the Guide for the Care and Use of Laboratory Animals. An Institutional Animal Care and Use Committee (IACUC) approved all animal protocols.
Flow Cytometry
Bone marrow mononuclear cells (BMNCs), peripheral blood mononuclear cells (PBMNCs), and tumor cells were harvested from mice implanted with tumors. Red blood cells were lysed using ACK (Cambrax) lysis buffer, followed by staining with rat anti-mouse CD11b (Myletnyi Biotech) conjugated with allophycocyanin (APC). To exclude dead cells, 7AAD (aminoactinomycin D; BD Biosciences, San Diego, CA, USA) was added to all samples before data acquisition in the FACS instrument (BD Biosciences).
Animals and Cell Lines
Female C57BL/6, BALB/c, and BALB/c nude were obtained from Charles River. RAG2 À/À mice were from Jackson labs. flt tk À/À mice were generated as described (Hiratsuka et al., 1998) . flt-1 tk, rag2 double ko mice were generated by crossing flt-1 tk À/À with rag2 À/À mice. Cell lines were obtained from ATCC. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) . Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439.
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